Skip to main content

AccuType® CP: Importance of Genotyping

AccuType CP conveniently identifies the genetic mutation of the CYP2C19 genotypes (*2,*3,*4,*5) that cause clopidogrel resistance, and determines if a patient should be prescribed clopidogrel. It reports if patients are a poor, intermediate or extensive metabolizer of the drug clopidogrel:

Metabolizer Types Clinical Interpretation
Hyperextensive - HM Increased bleeding risk
Extensive - EM Standard clopidogrel dose recommended
Intermediate - IM Increase clopidogrel dose or consider alternate therapy
Poor - PM

Our genetic counselors can provide additional assistance with AccuType CP results interpretation. Call 1-866-GENE-INFO (1-866-436-3463).


  1. Gladding P, et al. Pharmacogenetics Testing for Clopidogrel Using the Rapid INFINITI Analyzer, Journal of the American College of Cardiology: Cardiovascular Interventions 2009; 2:1095-1101.
  2. Mega et al. Cytochrome P-450 Polymorphisms and Response to Clopidogrel, New England Journal of Medicine 2009; 22; 360 (4): 354-362.
  3. Simon T, et al. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. New England Journal of Medicine 2009; 360 (4): 363-375.
  4. Hulot et al, Cardiovascular Risk in Clopidogrel Treated Patients According to Cytochrome P450 2C19*2. Loss of Function Allele or Proton Pump Inhibitor Co-administration: A Systematic Meta-Analysis JACC 2010. 56(2) 134-143.
  5. Mega et al, Reduced Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients treated with Clopidogrel Predominantly for PCI: A Meta-Analysis. JAME 2010; 304 (16) 1821- 1830.